REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022
- Interim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS I to be presented
The oral presentations will be presented as follows:
Abstract Title: Treatment of cardiac, neurologic, and skeletal manifestations of murine MPS I with AAV9-IDUA: Efficacy study of vector dose and route of administration
Presenter:
Date/Time: Tuesday, February 8, 2022,
Abstract Title: RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in-human study
Presenter: Roberto Giugliani, M.D., Ph.D., Professor,
Date/Time: Wednesday, February 9, 2022,
Abstract Title: RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in-human study
Presenter:
Date/Time: Wednesday, February 9, 2022,
Abstract Title: Identification of a biomarker that differentiates neuronopathic forms of MPS I and MPS II
Presenter:
Date/Time: Thursday, February 10, 2022,
Abstract Title: Establishment of in vitro model of CLN2 retinopathy using human induced pluripotent stem cells
Presenter:
Date/Time: Friday, February 11, 2022,
The poster presentations will be presented as follows:
Abstract Title: Safety, Pharmacodynamics and Efficacy of AAV9.hCLN2 in Preclinical Studies (poster LB-10)
Presenter:
Date/Time:
Abstract Title: Comparative effectiveness of intravenous and intrathecal AAV9.CB7.hIDS (RGX-121) in a murine model of mucopolysaccharidosis type II (poster #287)
Presenter:
Date/Time:
Abstract: Title: The Expanded Neuronal Ceroid Lipofuscinosis 2 (CLN2) Clinical Rating Scale for Motor and Language Function: Development and Inter-Rater Reliability (poster #239)
Presenter:
Date/Time:
Abstract Title: Natural History of Neurodevelopment in Neuronopathic Mucopolysaccharidosis Type II (MPS II):
Presenter:
Date/Time:
Abstract Title: Beyond the normative data: Understanding the Bayley Scales of
Presenter:
Date/Time:
Abstract Title: Beyond the normative data: Understanding the Mullen Scales of Early Learning (MSEL)
Presenter:
Date/Time:
Abstract Title: Pilot study of novel optokinetic nystagmus-based visual acuity test in children with CLN2 disease (poster #218)
Presenter:
Date/Time:
About REGENXBIO Inc.
Contacts:
Corporate Communications
dcormack@regenxbio.com
Investors:
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-18th-annual-worldsymposium-2022-301471241.html
SOURCE